多模态影像与无均整器模式前列腺立体定向消融放疗的安全性和可行性
41例低中危前列腺癌患者接受MR/CT融合勾画、基准标记定位和Varian RapidArc无均整器模式立体定向消融放疗,所有计划均达到临床靶区D99%≥95%和计划靶区D95%≥95%,78.0%计划满足全部直肠剂量约束,急性泌尿生殖道1级症状在治疗第5次时升至90.2%后回落,作者认为该技术可行、安全且高效。
要点
- 所有41例计划均达到临床靶区D99%≥95%和计划靶区D95%≥95%。
- 78.0%计划满足全部直肠剂量约束,V18 Gy≤35%达标率95.1%,V28 Gy≤10%达标率80%。
- 治疗第5次时1级急性泌尿生殖道症状发生率达90.2%,第18周降至52.5%。
核心结论
- 作者认为该计划和实施技术可行、安全且高效,能可靠地给予前列腺均匀剂量并限制邻近结构高剂量,可在进一步随机研究方案中安全应用。
研究设计与样本
- 单臂可行性研究,纳入41例低中危前列腺癌患者,初始前列腺特异性抗原≤20 ng/ml、Gleason评分6-7,采用MR/CT融合勾画前列腺±精囊腺、基准标记定位、锥形束CT验证,Varian RapidArc无均整器模式实施放疗。
关键影像表现/征象
- 所有患者均获得临床可接受的治疗计划,所有计划达到临床靶区D99%≥95%和计划靶区D95%≥95%。
- 直肠剂量约束V18 Gy≤35%达标率95.1%,V28 Gy≤10%达标率80%,78.0%(32/41)计划满足全部直肠剂量约束。
- 1级急性泌尿生殖道症状基线53.7%,治疗第5次90.2%[95%CI 76.8-97.3%](p=0.0005),第4周78.0%(62.4-89.4%),第10周75.0%(58.8-87.3%),第18周52.5%(36.1-68.5%)(p=1.00)。
- 急性胃肠道症状基线5%,治疗第5次46.3%[95%CI 30.7-62.6%],第4周43.9%[95%CI 28.5-60.3%],第10周25.0%(11.1-42.3%),第18周降至[-20.095% CI 12.7-41.2](p=0.039)。
- 75.6%(31/41)患者在治疗期间或治疗后出现1-2级毒性。
临床应用与阅片要点
- 采用MR/CT融合勾画前列腺±精囊腺、基准标记匹配锥形束CT验证,并以无均整器模式实施立体定向消融放疗,作者认为该技术可行、安全且高效。
- 作者认为该技术可在进一步随机研究方案中安全应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate feasibility and safety of stereotactic ablative radiotherapy in the management of prostate cancer while employing MR/CT fusion for delineation, fiducial marker seeds for positioning and Varian RapidArc with flattening filter free (FFF) delivery.
METHODS: 41 patients were treated for low-intermediate risk prostate cancer with initial prostate-specific antigen of ≤20 ng ml-1, Gleason score 6-7. Patients had MR/CT fusion for delineation of prostate ±seminal vesicles. CT/MR fusion images were used for delineation and planned using flattening filter free modality. Verification on treatment was cone beam CT imaging with fiducial markers for matching. Patients had Radiation Therapy Oncology Group scoring for genitourinary and gastointestinal symptoms at baseline, week 4, 10 and 18.
RESULTS: Clinically acceptable plans were achieved for all patients, all plans achieved the objective clinical target volume D99% ≥ 95%, and for planning target volume D95% ≥ 95%. Rectum dose constraints were met for 95.1% for V18 Gy ≤ 35%, 80% V28 Gy ≤ 10%. A total of 32 (78.0%) plans achieved all rectum dose constraints. Grade 1 acute genitourinary symptoms were 53.7% of patients at baseline, 90.2% [95% CI (76.8-97.3%)] (p = 0.0005) at treatment 5, falling to 78.0% (62.4-89.4%) at week 4, and 75.0% (58.8-87.3%) by week 10 and 52.5% (36.1-68.5%) (p = 1.00) at week 18. Acute gastrointestinal symptoms were 5% at baseline, 46.3% [95% CI (30.7-62.6%)] at treatment 5, week 4 43.9% [95% CI (28.5-60.3%)], week 10 25.0% (11.1-42.3%), and declined slightly by week 18 [-20.095% CI (12.7-41.2)] p = 0.039. Overall 75.6% (31/41) of patients experienced Grade 1-2 toxicity during or after treatment.
CONCLUSION: This planning and delivery technique is feasible, safe and efficient. A homogeneous dose can be delivered to prostate with confidence, whilst limiting high dose to nearby structures. The use of this technology can be applied safely within further randomized study protocols. Advances in knowledge: Multimodality imaging for delineation and linac-based image-guided RT with FFF for the treatment of prostate stereotactic ablative radiotherapy.
引用
- Duffton A, Sadozye A, Devlin L, et al. Safety and feasibility of prostate stereotactic ablative radiotherapy using multimodality imaging and flattening filter free. Br J Radiol. 2018. PMID: 29338305. doi:10.1259/bjr.20170625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。